Drug Profile
LY 3045697
Alternative Names: LY-3045697Latest Information Update: 02 Oct 2015
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 01 Sep 2013 Eli Lilly completes a phase I trial in Healthy volunteers in the Netherlands (NCT01821703)
- 25 Jul 2013 Eli Lilly completes a phase I volunteer trial in Netherlands (NCT01750853)
- 09 Jul 2013 Eli Lilly initiates enrolment in a phase I trial in Cardiovascular disorders (healthy volunteers) in Netherlands (NCT01821703)